applepharmaceutical@gmail.com
secukinumab-150mg

PRODUCT DETAILS

Composition : Secukinumab
Strength availability : 150mg
Form : injection
Pack : 150mg in 1 vial
for MORE INFORMATION !!!

Secukinumab belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful joints
Scapho is a prescription drugs which is used under proper guidance of medical oncologist

INDICATION

Scapho indicated for the treatment of following condition
Plaque Psoriasis
Psoriatic arthritis
Ankylosing spondylitis.

DOSAGE

Plaque Psoriasis:
Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
For some patientsmay be acceptable containing dose of 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Recommended dosage
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Ankylosing Spondylitis:
Given with or without a loading dosage by SC injection
Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without a loading dose is administrated150 mg SC q4wk

MECHANISM

Secukinumab mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and is found in peak concentrations in psoriasis plaques.
Secukinumab consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.

ADME

Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days
Volume of distribution is 7.1 – 8.6 (IV administration)
The drug scapho is Metabolized via intracellular catabolism.
Scapho has half-life is 22-31 days

PRECAUTION

Scapho may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
Before to initiation of scapho,start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
May infuriate Crohn disease
Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment

DRUG INTERACTION

Live vaccinations combination with scapho should be avoided
CYP450 substrates concomitant use with scapho injection may altered by increased levels of certain cytokines.

CONTRAINDICATION

Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients

STORAGE

Store the drug at 2℃ to 8℃.

MISSED DOSE

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule.

SIDE EFFECTS

• Infections
• Nasopharyngitis
• Diarrhea
• URT infection
• Rhinitis
• Oral herpes
• Pharyngitis
• Urticaria
• Rhinorrhoea


We'd Like to Hear From You!

PRESCRIPTION POLICY

1. myapplepharma.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. myapplepharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the myapplepharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. myapplepharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from myapplepharma.com.
6. At myapplepharma.com, a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.